<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>43(1)</volume><submitter>Israni M</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Due to the absence of curative treatments for inborn errors of immunity (IEI), children born with IEI require long-term follow-up for disease manifestations and related complications that occur over the lifespan. Effective transition from pediatric to adult services is known to significantly improve adherence to treatment and long-term outcomes. It is currently not known what transition services are available for young people with IEI in Europe.&lt;h4>Objective&lt;/h4>To understand the prevalence and practice of transition services in Europe for young people with IEI, encompassing both primary immunodeficiencies (PID) and systemic autoinflammatory disorders (AID).&lt;h4>Methods&lt;/h4>A survey was generated by the European Reference Network on immunodeficiency, autoinflammatory, and</pubmed_abstract><journal>Journal of clinical immunology</journal><pagination>206-216</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9840587</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Current Transition Practice for Primary Immunodeficiencies and Autoinflammatory Diseases in Europe: a RITA-ERN Survey.</pubmed_title><pmcid>PMC9840587</pmcid><pubmed_authors>Carreras C</pubmed_authors><pubmed_authors>McCann L</pubmed_authors><pubmed_authors>Alsina L</pubmed_authors><pubmed_authors>Wouters C</pubmed_authors><pubmed_authors>Ritterbusch H</pubmed_authors><pubmed_authors>Dalm V</pubmed_authors><pubmed_authors>Carrabba M</pubmed_authors><pubmed_authors>Burns SO</pubmed_authors><pubmed_authors>Barzaghi F</pubmed_authors><pubmed_authors>Skeffington S</pubmed_authors><pubmed_authors>Hague H</pubmed_authors><pubmed_authors>Avramovic MZ</pubmed_authors><pubmed_authors>McDermott E</pubmed_authors><pubmed_authors>Nicholson B</pubmed_authors><pubmed_authors>Carne E</pubmed_authors><pubmed_authors>Israni M</pubmed_authors><pubmed_authors>Kelecic J</pubmed_authors><pubmed_authors>Sanchez-Manubens J</pubmed_authors><pubmed_authors>Insalaco A</pubmed_authors><pubmed_authors>Plebani A</pubmed_authors><pubmed_authors>van Laar JAM</pubmed_authors><pubmed_authors>Hayward G</pubmed_authors><pubmed_authors>Neth O</pubmed_authors><pubmed_authors>RITA-ERN Transition Working Group Consortium</pubmed_authors><pubmed_authors>Moschese V</pubmed_authors><pubmed_authors>Soler-Palacin P</pubmed_authors><pubmed_authors>Korganow AS</pubmed_authors><pubmed_authors>Ogunjimi B</pubmed_authors><pubmed_authors>Seoane Reula ME</pubmed_authors><pubmed_authors>Arkwright PD</pubmed_authors><pubmed_authors>Aalto K</pubmed_authors><pubmed_authors>Brogan P</pubmed_authors><pubmed_authors>Cattalini M</pubmed_authors><pubmed_authors>Ekwall O</pubmed_authors><pubmed_authors>Wulffraat NM</pubmed_authors><pubmed_authors>van der Werff Ten Bosch JE</pubmed_authors><pubmed_authors>Faust SN</pubmed_authors><pubmed_authors>Canessa C</pubmed_authors><pubmed_authors>Rossi-Semerano L</pubmed_authors><pubmed_authors>Guffroy A</pubmed_authors><pubmed_authors>Gennery AR</pubmed_authors><pubmed_authors>Nordin J</pubmed_authors><pubmed_authors>Fingerhutova S</pubmed_authors><pubmed_authors>Mendez-Echevarria A</pubmed_authors><pubmed_authors>Cimaz R</pubmed_authors><pubmed_authors>Anton J</pubmed_authors><pubmed_authors>Mahlaoui N</pubmed_authors><pubmed_authors>Meyts I</pubmed_authors><pubmed_authors>Lachmann H</pubmed_authors><pubmed_authors>Obici L</pubmed_authors><pubmed_authors>Villar C</pubmed_authors><pubmed_authors>Brodszki O</pubmed_authors><pubmed_authors>Marques L</pubmed_authors><pubmed_authors>Herlin T</pubmed_authors><pubmed_authors>Gilliaux O</pubmed_authors><pubmed_authors>Rimmer R</pubmed_authors><pubmed_authors>Riordan A</pubmed_authors><pubmed_authors>Campbell M</pubmed_authors><pubmed_authors>Berg S</pubmed_authors><pubmed_authors>Dellepiane RM</pubmed_authors><pubmed_authors>Warnatz K</pubmed_authors><pubmed_authors>Seppanen Mikko RJ</pubmed_authors><pubmed_authors>Devlin LA</pubmed_authors><pubmed_authors>Gonzales-Granado LI</pubmed_authors><pubmed_authors>Solis L</pubmed_authors><pubmed_authors>Amin T</pubmed_authors><pubmed_authors>Sediva A</pubmed_authors><pubmed_authors>Jelusic M</pubmed_authors><pubmed_authors>Goffin L</pubmed_authors><pubmed_authors>Santamaria M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Current Transition Practice for Primary Immunodeficiencies and Autoinflammatory Diseases in Europe: a RITA-ERN Survey.</name><description>&lt;h4>Background&lt;/h4>Due to the absence of curative treatments for inborn errors of immunity (IEI), children born with IEI require long-term follow-up for disease manifestations and related complications that occur over the lifespan. Effective transition from pediatric to adult services is known to significantly improve adherence to treatment and long-term outcomes. It is currently not known what transition services are available for young people with IEI in Europe.&lt;h4>Objective&lt;/h4>To understand the prevalence and practice of transition services in Europe for young people with IEI, encompassing both primary immunodeficiencies (PID) and systemic autoinflammatory disorders (AID).&lt;h4>Methods&lt;/h4>A survey was generated by the European Reference Network on immunodeficiency, autoinflammatory, and</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jan</publication><modification>2025-04-22T03:59:02.23Z</modification><creation>2025-04-05T20:53:45.13Z</creation></dates><accession>S-EPMC9840587</accession><cross_references><pubmed>36222999</pubmed><doi>10.1007/s10875-022-01345-y</doi></cross_references></HashMap>